15.08.2022 - Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene .
Longeveron Inc. (NASDAQ:NASDAQ:LGVN) Q2 2022 Earnings Conference Call August 12, 2022 08:30 AM ET Company Participants Elsie Yau - Stern Investor Relations Chris Min - Interim Chief.
Longeveron Inc (LGVN) CEO Geoff Green on Q1 2022 Results - Earnings Call Transcript seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.